Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 8 of 65 · 3079 articles
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Genetics and genomics, and Research and clinical trials. The original article is from Gut.
Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Research and clinical trials. The original article is from Gut.
Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...
The trial is testing a personalized approach that uses CLE to find foods that directly disrupt the intestinal barrier and then removes those foods to see if patients feel and biologically improve. If successful, it could...
Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.
A phase 2 trial tested whether repurposing fenofibrate (a lipid-lowering PPAR-α agonist) added to mesalamine can reduce disease activity and improve quality of life in adults with mild-to-moderate ulcerative colitis.
This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...
Researchers are investigating whether a specific gut bacterium (Pilosibacter rotomagensis) is linked to lower intestinal inflammation after surgery for ileal Crohn's disease. If true, this could point toward new...
This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...
The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...
This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...
The study suggests L‑proline can reduce colitis in a mouse model and reshapes the gut microbiome, raising the possibility that amino-acid–based dietary strategies might influence intestinal inflammation through...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
People with ulcerative colitis may be interested because the study explores a way to boost curcumin’s activity and suggests gut microbiota changes could underlie protection against colitis.
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...
A positive pre‑IND response from the FDA makes it more likely this stem‑cell therapy will reach a formal Phase 2 trial, which could eventually expand treatment options for people with refractory or fistulising Crohn’s...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Fistula and Research and clinical trials.
If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.
The study suggests B cells can protect against colitis through secretory IgA that reshapes the gut microbiota, a mechanism separate from known regulatory B cell cytokines. This could point to new directions for IBD...
This review addresses whether people with IBD face higher breast cancer risk and how treatments for one disease might affect the other—questions many patients and clinicians raise when cancer and IBD overlap.
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Drug Discovery, and Research and clinical trials. The original article is from Molecular Biology Reports.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.
Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...
Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...
People with ulcerative colitis may be interested because the review identifies flavonoids in propolis as compounds that reduce inflammation and strengthen the gut barrier in animal models, and it highlights strategies to...
Researchers are exploring new oral delivery carriers that could deliver drugs directly to inflamed intestinal sites while also modulating immune responses and the gut microbiome. If translated, these approaches might...
A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...
A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Mansoura Journal of Biology.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from The Egyptian Journal...
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
Improving mesalazine delivery could increase drug reaching the colon and potentially improve treatment for ulcerative colitis. A formulation that both enhances dissolution/permeability and offers mechanistic synergy...
The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.
People with IBD often ask about dietary supplements. This systematic review suggests some randomized-trial evidence that polyphenol supplements—especially curcumin—may help induce clinical improvement in ulcerative...
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
A colon-targeted IFX formulation could deliver the drug directly to inflamed tissue, potentially improving effectiveness and lowering systemic side effects or dosing complexity for people with ulcerative colitis.
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...
The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
The study suggests that using Advice & Guidance instead of elective referral was associated with a longer time to diagnosis for IBD, which could influence how primary care referral pathways are evaluated or designed.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from gastroendonews.com.
Patients with PsA and clinicians choosing long‑term biologic therapy may care about both durability of PsA control and safety signals for related inflammatory conditions like IBD and uveitis. This analysis reports...
